Molecularly imprinted polymer-based SAW sensor for label-free detection of cerebral dopamine neurotrophic factor protein
| Autor: | Mart Saarma, Roman Boroznjak, Andres Öpik, Jekaterina Reut, Vitali Syritski, Anna Kidakova |
|---|---|
| Přispěvatelé: | Institute of Biotechnology |
| Jazyk: | angličtina |
| Rok vydání: | 2020 |
| Předmět: |
BIOMARKER
ELECTRODES 02 engineering and technology 010402 general chemistry Pretreatment method ISOTHERM 01 natural sciences CDNF Competitive binding Electrochemical polymerization Materials Chemistry Electrical and Electronic Engineering Instrumentation Cerebral dopamine neurotrophic factor Label free Molecularly imprinted polymer MANF SENSITIVE DETECTION Chemistry Neurodegenerative diseases Metals and Alloys RECOGNITION 3112 Neurosciences ELECTROCHEMICAL DETECTION 021001 nanoscience & nanotechnology Condensed Matter Physics 0104 chemical sciences Surfaces Coatings and Films Electronic Optical and Magnetic Materials Potential biomarkers ENDOTHELIAL GROWTH-FACTOR Surface acoustic wave sensor ELISA m-Phenylenediamine 0210 nano-technology Selectivity Biomedical engineering |
| Popis: | In this study we report on a surface acoustic wave (SAW) sensor modified with a molecularly imprinted polymer (MIP) film that selectively recognizes the cerebral dopamine neurotrophic factor (CDNF) protein, a potential biomarker for early-stage diagnosis and/or the follow-up of neuroprotective therapies. CDNF-MIP as a synthetic recognition element was prepared by a simple electrochemical surface imprinting approach allowing its reliable interfacing with SAW sensor. The optimal thickness of the MIP layer as well as a suitable pretreatment method were adjusted to improve the recognition capacity and selectivity of the resulting CDNF-MIP sensor. The 4.7 nm thick CDNF-MIP layers treated in 0.04 mg/ml HSA solution demonstrated the highest relative rebinding towards CDNF. The selectivity of the sensor was studied by the carefully designed competitive binding experiments, which revealed that the sensor can sense CDNF confidently in a label-free manner starting from 0.1 pg/ml. We anticipate that the findings can be a premise for fabricating the desired cost-effective research or diagnostics tools in the field of neurodegenerative diseases. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|